Jubilant Therapeutics Inc., a biopharmaceutical organization propelling little particle modulators to address neglected clinical needs in oncology and immune system infections, today declared that <span style="color: #ff6600;"><a style="color: #ff6600;" href="https://www.aacr.org/meeting/aacr-annual-meeting-2020/coronavirus-information/">preclinical information of double LSD1 and HDAC6 inhibitor JBI-802, will be introduced in a banner meeting at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II.</a> </span>The preclinical information exhibited that JBI-802 has solid viability in numerous in vivo malignant growth models interceded by LSD1 and HDAC6 restraint, while showing fantastic selectivity against different HDACs and better in vivo adequacy looked at than single specialists focusing on LSD1 or HDAC6.

<em>We are excited to reveal these new data from our study of JBI-802 whose first-in-class dual mechanism of action targets the overexpression of two proteins, while exhibiting a favorable tolerability profile."</em>
Syed Kazmi, President and Chief Executive Officer

&nbsp;